Market Overview

UPDATE: ISI Group Initiates Market Weight, $45 PT on Illumina on Soft Demand Environment

Share:
Related ILMN
3 Biotech Stocks Bucking Short Interest Trends
Is It Closing Time At The Biotech Bar?
The Zacks Analyst Blog Highlights: Horizon Pharma, NewLink Genetic and llumina - Press Releases (Zacks)

ISI Group initiated its coverage on Illumina (NASDAQ: ILMN) with a Market Weight rating and a $45 price target.

ISI Group noted, "We are initiating coverage on shares of Illumina with a Market Weight rating and a price target of $45.00, which on a forward basis equates to ~12x EV/EBITDA and ~25x operating EPS. Our thesis for ILMN is based on our view that strong growth in MiSeq and an improving HiSeq through-put will help to offset an increasingly challenging budgetary environment, that microarray growth will remain modest as demand for emerging applications helps to soften a slowdown in legacy GWAS, and that recent strategic interest in asset (e.g. Roche's hostile bid) provides a modest valuation premium."

Illumina closed at $40.60 on Monday.

Latest Ratings for ILMN

DateFirmActionFromTo
Mar 2015UBSInitiates Coverage onBuy
Jan 2015BarclaysMaintainsEqual-weight
Jan 2015JP MorganMaintainsOverweight

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ILMN)

Around the Web, We're Loving...